The Quiet Risk in 2026 INDs: When Clinical Pharmacology Is Treated as a Deliverable Instead of a Strategy
Many 2026 INDs are already being scoped. Budgets are being finalized, CROs are being shortlisted, and timelines are being compressed. In that environment, clinical pharmacology often becomes something to be delivered rather than something to be designed. Analyses are commissioned because the IND needs them, not because a decision requires them. The risk here is […]